199 related articles for article (PubMed ID: 34830408)
1. FOXO3a and Its Regulators in Prostate Cancer.
Habrowska-Górczyńska DE; Kozieł MJ; Kowalska K; Piastowska-Ciesielska AW
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830408
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
Li Y; Wang Z; Kong D; Li R; Sarkar SH; Sarkar FH
J Biol Chem; 2008 Oct; 283(41):27707-27716. PubMed ID: 18687691
[TBL] [Abstract][Full Text] [Related]
3. Critical role of FOXO3a in carcinogenesis.
Liu Y; Ao X; Ding W; Ponnusamy M; Wu W; Hao X; Yu W; Wang Y; Li P; Wang J
Mol Cancer; 2018 Jul; 17(1):104. PubMed ID: 30045773
[TBL] [Abstract][Full Text] [Related]
4. miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A.
Qiu X; Dou Y
Biomed Pharmacother; 2017 Apr; 88():430-435. PubMed ID: 28122308
[TBL] [Abstract][Full Text] [Related]
5. β-arrestin1-medieated inhibition of FOXO3a contributes to prostate cancer cell growth in vitro and in vivo.
Kong Z; Deng T; Zhang M; Zhao Z; Liu Y; Luo L; Cai C; Wu W; Duan X
Cancer Sci; 2018 Jun; 109(6):1834-1842. PubMed ID: 29676828
[TBL] [Abstract][Full Text] [Related]
6. [FOXO3a signaling pathway in prostate cancer: Progress in studies].
Tao Y; Li LL; Liu SH; Hong M
Zhonghua Nan Ke Xue; 2020 Aug; 26(8):745-750. PubMed ID: 33377739
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of FOXO3A during prostate cancer progression.
Shukla S; Shukla M; Maclennan GT; Fu P; Gupta S
Int J Oncol; 2009 Jun; 34(6):1613-20. PubMed ID: 19424579
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.
Shukla S; Bhaskaran N; Maclennan GT; Gupta S
Prostate; 2013 Oct; 73(14):1507-17. PubMed ID: 23765843
[TBL] [Abstract][Full Text] [Related]
9. FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
Imada K; Shiota M; Kuroiwa K; Sugimoto M; Abe T; Kohashi K; Yokomizo A; Eto M; Naito S; Oda Y
Prostate; 2017 Feb; 77(2):145-153. PubMed ID: 27699813
[TBL] [Abstract][Full Text] [Related]
10. Potent FOXO3a Activators from Biologically Active Compound Library for Cancer Therapeutics: An in silico Approach.
Manoharan S; Vedagiri H; Perumal E
Appl Biochem Biotechnol; 2023 Aug; 195(8):4995-5018. PubMed ID: 37017892
[TBL] [Abstract][Full Text] [Related]
11. FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.
Brucker DP; Maurer GD; Harter PN; Rieger J; Steinbach JP
Int J Oncol; 2016 Dec; 49(6):2399-2410. PubMed ID: 27840901
[TBL] [Abstract][Full Text] [Related]
12. NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription.
Won KJ; Kim BK; Han G; Lee K; Jung YJ; Kim HM; Song KB; Chung KS; Won M
Apoptosis; 2014 Jan; 19(1):179-90. PubMed ID: 24085402
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.
Dey P; Ström A; Gustafsson JÅ
Oncogene; 2014 Aug; 33(33):4213-25. PubMed ID: 24077289
[TBL] [Abstract][Full Text] [Related]
14. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway.
Lu Z; Zhou R; Kong Y; Wang J; Xia W; Guo J; Liu J; Sun H; Liu K; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2016; 16(5):455-65. PubMed ID: 26638886
[TBL] [Abstract][Full Text] [Related]
15. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Aldonza MB; Hong JY; Lee SK
Exp Mol Med; 2017 Jan; 49(1):e286. PubMed ID: 28104912
[TBL] [Abstract][Full Text] [Related]
17. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.
Zhou R; Lu Z; Liu K; Guo J; Liu J; Zhou Y; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2015; 14(9):860-71. PubMed ID: 25431082
[TBL] [Abstract][Full Text] [Related]
18. Forkhead box protein O3 suppresses uveal melanoma development by increasing the expression of Bcl‑2‑like protein 11 and cyclin‑dependent kinase inhibitor 1B.
Yan F; Liao R; Lin S; Deng X; Little PJ; Zheng W
Mol Med Rep; 2018 Feb; 17(2):3109-3114. PubMed ID: 29257235
[TBL] [Abstract][Full Text] [Related]
19. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
Li Y; Wang Z; Kong D; Murthy S; Dou QP; Sheng S; Reddy GP; Sarkar FH
J Biol Chem; 2007 Jul; 282(29):21542-50. PubMed ID: 17522055
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
